20/20 Biolabs, Inc. Common Stock (AIDX)vsMerck & Company Inc (MRK)
AIDX
20/20 Biolabs, Inc. Common Stock
$1.49
-1.97%
HEALTHCARE · Cap: $15.62M
MRK
Merck & Company Inc
$113.56
+0.36%
HEALTHCARE · Cap: $277.02B
Smart Verdict
WallStSmart Research — data-driven comparison
Merck & Company Inc generates 3215782% more annual revenue ($65.77B vs $2.05M). MRK leads profitability with a 13.6% profit margin vs -182.8%. MRK earns a higher WallStSmart Score of 53/100 (C-).
AIDX
Avoid15
out of 100
Grade: F
MRK
Buy53
out of 100
Grade: C-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for AIDX.
Margin of Safety
-15.7%
Fair Value
$97.76
Current Price
$113.56
$15.80 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
No standout strengths identified
Mega-cap, among the largest globally
Every $100 of equity generates 37 in profit
Strong operational efficiency at 38.1%
Generating 2.9B in free cash flow
Areas to Watch
0.4% revenue growth
0.0% earnings growth
Smaller company, higher risk/reward
ROE of -503.0% — below average capital efficiency
Premium valuation, high expectations priced in
4.9% revenue growth
Weak financial health signals
Expensive relative to growth rate
Comparative Analysis Report
WallStSmart ResearchBull Case : AIDX
AIDX has a balanced fundamental profile.
Bull Case : MRK
The strongest argument for MRK centers on Market Cap, Return on Equity, Operating Margin.
Bear Case : AIDX
The primary concerns for AIDX are Revenue Growth, EPS Growth, Market Cap.
Bear Case : MRK
The primary concerns for MRK are P/E Ratio, Revenue Growth, Piotroski F-Score.
Key Dynamics to Monitor
AIDX profiles as a turnaround stock while MRK is a value play — different risk/reward profiles.
MRK carries more volatility with a beta of 0.28 — expect wider price swings.
MRK is growing revenue faster at 4.9% — sustainability is the question.
MRK generates stronger free cash flow (2.9B), providing more financial flexibility.
Bottom Line
MRK scores higher overall (53/100 vs 15/100). Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
20/20 Biolabs, Inc. Common Stock
HEALTHCARE · MEDICAL DEVICES · USA
20/20 Biolabs, Inc. (ticker: AIDX) is a forward-thinking biotechnology company dedicated to advancing genomic research and diagnostics through innovative laboratory services. By focusing on improving the accuracy and efficiency of genetic testing for both clinical and research applications, the company is at the forefront of molecular diagnostics. With a strong commitment to harnessing cutting-edge technologies, 20/20 Biolabs is well-positioned to lead the charge in personalized medicine as the demand for genomic data accelerates. The company’s strategic initiatives and robust market positioning signal a promising growth trajectory in the dynamic biotechnology sector.
Merck & Company Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Merck & Co. is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668.
Visit Website →Compare with Other MEDICAL DEVICES Stocks
Want to dig deeper into these stocks?